Follow up after Treated Circumscribed Choroidal Haemangioma with Photodynamic Therapy

Published: 30-09-2015
Last updated: 21-04-2024

Long-term follow up of patients treated with limited PDT, for a symptomatic circumscribed choroidal hamangioma, in search of possible late unwanted side effects of PDT treatment and recurrence of leakage.

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Retina, choroid and vitreous haemorrhages and vascular disorders
Study type	Observational invasive

Summary

ID

NL-OMON42127

Source
ToetsingOnline

Brief title
Follow up of Circumscribed Choroidal Haemangioma

Condition

- Retina, choroid and vitreous haemorrhages and vascular disorders

Synonym
'Circumscribed Choroidal Haemangioma' 'vascular tumor of the choroid'

Research involving
Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum
Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: Circumscribed Choroidal Haemangioma, Photodynamic Therapy

Outcome measures

Primary outcome

The results of examinations will provide information of the effectiveness of

limited PDT after the first year(s), and possible late complications, including

recurrence.

Secondary outcome

nvt

Study description

Background summary

Circumscribed choroidal haemangioma (CCH) is an uncommon benign vascular tumor of the choroid. Untreated, this tumor can result in permanent vision loss. Photodynamic therapy (PDT) is at present the preferred treatment because of good results and the low risk of complications.

Study objective

Long-term follow up of patients treated with limited PDT, for a symptomatic circumscribed choroidal hamangioma, in search of possible late unwanted side effects of PDT treatment and recurrence of leakage.

Study design

Prospective transversal observational cohort study.
All included patients will have a full ophthalmologic examination including visual acuity, slitlamp biomicroscopy, Optical Coherence Tomography (OCT) with enhanced depth imaging, Fundus Autofluorescence (FAF), Fluorescein angiography in combination with Indocyanine Green Angiography (FA and ICGA) and Ultrasonography.

Study burden and risks

nvt

Contacts

Public
Academisch Medisch Centrum

Meibergdreef 9
Amsterdam 1105 AZ
NL
Scientific
Academisch Medisch Centrum

Meibergdreef 9
Amsterdam 1105 AZ
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Patients treated for circumscribed choroidal haemangioma with PDT in the AMC

Exclusion criteria

none

Study design

Design

Study type: Observational invasive

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	22-04-2016
Enrollment:	35
Type:	Actual

Ethics review

Approved WMO Date:	30-09-2015
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO Date:	19-01-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL52013.018.14